Background: Prostate cancer (PCa) is the second most commonly diagnosed malignancy in men worldwide. Accurate pre-biopsy characterization of prostatic lesions remains a clinical challenge. Multiparametric magnetic resonance imaging (mpMRI), interpreted using Prostate Imaging-Reporting and Data System (PI-RADS) v2.1, has emerged as a valuable noninvasive diagnostic tool. This study evaluates the diagnostic performance of mpMRI with histopathological correlation in detecting clinically significant PCa at a tertiary care center in India. Materials and Methods: A prospective observational study was conducted on 63 male patients undergoing pre-biopsy mpMRI on a 1.5-T GE Signa HDxT system. Sequences included T2-weighted imaging, diffusion-weighted imaging with apparent diffusion coefficient (ADC) mapping, and dynamic contrast-enhancement (DCE) imaging. Lesions were scored using PI-RADS v2.1. Histopathological examination served as the gold standard. Diagnostic performance metrics were calculated. Results: Among 63 patients, 42 (65.6%) had adenocarcinoma, and 21 (32.8%) had benign pathology. Using PI-RADS 3–5 as positive, mpMRI showed 100% sensitivity, 47.6% specificity, 79.2% positive predictive value, 100% negative predictive value (NPV), and 82.53% accuracy. ADC hypointensity and lesion margin demonstrated the highest sensitivity (100%), while DCE showed the highest specificity (45.45%). PI-RADS 4 had 100% malignancy risk; PI-RADS 5 had 75%. Conclusion: mpMRI with PI-RADS v2.1 is a highly sensitive modality with excellent NPV, enabling reliable exclusion of significant malignancy and supporting its role in guiding biopsy decisions.
No takes yet. Share an insight, caveat, or question.
Deshmukh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: